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TO THE EDITOR
Staphylococcal scalded skin syndrome
(SSSS) is a generalized blistering skin
disease caused by Staphylococcus aur-
eus producing exfoliative toxin (ET). ET
is a serine protease that specifically
digests desmoglein 1 (Dsg1), the auto-
immune target for pemphigus foliaceus
(PF). Out of 30 patients with SSSS, six
(20.0%) patients developed low titers of
anti-Dsg1 IgG, but no detectable anti-
Dsg3 IgG, 7 days or more after the
onset of the disease. Although other
genetic or environmental factors are
necessary for the full development of
pemphigus, this finding provides evi-
dence that infection could trigger the
autoimmune reaction.
A major question in understanding
the pathophysiology of autoimmune
disease is what triggers the immune
response. One postulated mechanism,
molecular mimicry, has been that
infectious agents might cause anti-
bodies that bind self-antigens, a good exa-
mple being streptococcal antigens in
rheumatic heart disease (Wucherpfennig,
2001). In such cases, the antibodies that
are produced against the infectious
agent are thought to coincidentally
crossreact with normal tissues. The
recent elucidation of the pathophysiol-
ogy of an antibody-mediated tissue-
specific autoimmune disease, PF, and
two related infectious diseases, bullous
impetigo (BI) and SSSS, all of which
target the same molecule, Dsg1, sug-
gested to us another mechanism by
which an infectious agent could trigger
an autoimmune response. In this
mechanism, we hypothesize that a
bacterial toxin could bind to and
partially degrade a self-antigen, with
the modified self-antigen triggering the
immune response.
Impetigo is the most common bac-
terial infection of children and 30% of
these patients have BI, which is caused
by S. aureus that produces ETs. SSSS is a
generalized form of BI, which occurs in
newborns, young children, and adults
with renal failure and/or who are
immunocompromised. In the early
1970s, ETs of two major serotypes,
ETA and ETB, were shown to produce
blisters in the superficial epidermis
when passively transferred to neonatal
mice (Melish and Glasgow, 1970). It
took almost 30 years to elucidate the
pathophysiological mechanism of ac-
tion of ETs, which have recently been
shown to be glutamate-specific serine
proteases that specifically bind and
cleave Dsg1 (Amagai et al., 2000).
Desmogleins are cadherin-type cell–-
cell adhesion molecules found in des-
mosomes and play a critical role in
maintaining tissue integrity in epithelial
and other tissues (Green and Gaudry,
2000).
Desmogleins are also affected in the
skin autoimmune blistering disease,
pemphigus (Payne et al., 2004). Among
four isoforms of desmoglein, Dsg1 is
targeted by IgG autoantibodies in PF,
which shows superficial epidermal blis-
ters with identical histological findings
to SSSS/BI. Thus, in both PF and SSSS/BI
the inactivation of Dsg1 causes super-
ficial blisters in skin.
If, as postulated above, altered anti-
gen, in this case Dsg1, could trigger an
immune response, we would expect
that some patients with SSSS or BI
produce at least low-level antibodies
against Dsg1. To address this hypo-
thesis, we examined a total of 58 serum
samples from 30 patients with SSSS
and 12 serum samples from 12 patients
with BI after informed consent with
Abbreviations: BI, bullous impetigo; Dsg1, desmoglein 1; ET, exfoliative toxin; PF, pemphigus foliaceus;
SSSS, staphylococcal scalded skin syndrome
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adherence to the Helsinki Guidelines
was obtained from patients or their
guardians (Table 1). The diagnosis was
confirmed by typical clinical findings as
well as by culture of S. aureus. We
tested the sera by ELISA and immuno-
blot analyses against recombinant
human Dsg1 and Dsg3 expressed in
the baculovirus system. For ELISA, we
used the cutoff value which was deter-
mined by receiver-operating-characteris-
tic curves as described previously (11.0
for Dsg1 ELISA, 10.0 for Dsg3 ELISA)
(Amagai et al., 1999).
We found that six out of 30 (20.0%)
cases with SSSS developed low titers of
anti-Dsg1 IgG autoantibodies as de-
tected by ELISA (4/30) or immunoblot
analyses (4/30), although none of them
developed any detectable anti-Dsg3
IgG antibodies during the course of
the study (Table 1). Although it was
difficult to obtain paired sera because
most of the patients were infants or
small children, four patients with SSSS
demonstrated the shift from negative to
positive anti-Dsg1 IgG. One patient
(SSSS no. 1 in Table 2, 10 months old,
female) developed anti-Dsg1 IgG at day
16 after the onset of SSSS, whereas she
did not have significant titers of anti-
Dsg1 IgG at days 3 and 10, and another
patient (SSSS no. 3, 14 months old,
female) showed a slight increase of
anti-Dsg1 IgG between days 4 and 9, as
determined by ELISA (Figure 1). Two
additional patients (SSSS no. 4, 3 years
old, female; SSSS no. 5, 4 years old,
female) developed anti-Dsg1 IgG be-
tween days 10 and 20 and days 7 and
14, respectively, as determined by
immunoblotting (Figure 2). Another
case of SSSS (SSSS no. 2, 4 years old,
female) showed positive anti-Dsg1 IgG
at days 10 and 15 by ELISA as well as
immunoblotting, although we could not
prove that she had negative anti-Dsg1
IgG at an earlier phase of the disease
(Figure 1). Finally, another patient with
Table 1. Anti-Dsg1 IgG production in patients with SSSS and bullous
impetigo
Anti-Dsg1 IgG Anti-Dsg3 IgG
Disease
Total cases
examined Male Female
Average age
(years) Total ELISA IB Total ELISA IB
SSSS 30 16 14 2.4 6 4 4 0 0 0
Bullous impetigo 12 7 5 5.3 0 0 0 0 0 0
Dsg1, desmoglein 1; SSSS, staphylococcal scalded skin syndrome.
Table 2. Summary of SSSS patients with production of low titers
of anti-Dsg1 IgG
Days ELISA IB
Patients Sex Age after onset Dsg1 Dsg3 Dsg1 Dsg3
SSSS no. 1 F 10 months 3 1.6 1.4  
10 3.2 2.4  
16 17.3 4.2  
SSSS no. 2 F 4 years 10 42.9 2.9 + 
15 33.5 2.0 + 
SSSS no. 3 F 14 months 4 8.8 0.9  
9 12.9 1.1  
SSSS no. 4 F 3 years 10 0.7 0.4  
20 1.2 0.7 + 
37 0.2 0.0 + 
SSSS no. 5 F 4 years 7 0.0 0.0  
14 0.0 0.0 + 
SSSS no. 6 F 2 years 6 11.0 0.0 + 
Dsg1, desmoglein 1; SSSS, staphylococcal scalded skin syndrome.
Bold values indicate positive ELISA scores.
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Figure 1. Seroconversion of anti-Dsg1 IgG
antibodies in patients with SSSS. Time course of
anti-Dsg1 IgG production as determined by ELISA
against Dsg1 after the onset of SSSS in three
patients. The dashed line indicates the cutoff value
(11.0) for Dsg1 ELISA. The cases shown in this
figure are as follows: closed circle, SSSS no. 1;
closed square, SSSS no. 2; closed triangle, SSSS
no. 3 in Table 2.
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Figure 2. Seroconversion of anti-Dsg1 IgG antibodies in patients with SSSS. Time course of anti-Dsg1
and anti-Dsg3 IgG production by immunoblot analysis against recombinant (a) Dsg1 and (b) Dsg3.
P: (a) a PF serum and (b) a PV serum as positive controls.
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SSSS had positive anti-Dsg1 IgG by
ELISA as well as immunoblotting,
although serum was obtained only at
day 6 (SSSS no. 6 in Table 2). No anti-
Dsg3 IgG was detected either by ELISA
or by immunoblotting in these patients
studied throughout their course, indi-
cating the specificity of the reactivity
against Dsg1 (Table 1). No apparent
IgM reactivity against Dsg1 or Dsg3
was detected by ELISA (data not
shown). None of the 12 patients with
BI, whose sera were taken with a range
of days 2–33, showed any detectable
IgG production against either Dsg1 or
Dsg3 as determined by ELISA and
immunoblotting (Table 1).
These findings indicate that a small
number of patients of SSSS develop low
titers of IgG antibodies specific for Dsg1
after binding and systemic digestion of
Dsg1 by staphylococcal ETs. This ob-
servation is specific for patients with
SSSS because none of the patients with
BI showed any sign of anti-Dsg1 anti-
body production. This may be because
a single episode of BI may be too
limited to cause an immune response.
Although none of these patients devel-
op PF after SSSS, which is not known as
a predisposing factor for PF, the findings
presented here provide evidence that
infection which modifies self-antigen
can trigger the production of IgG
autoantibodies against the self-antigen.
Of course, these patients do not devel-
op clinically overt PF. We would
speculate that other genetic or environ-
mental factors are needed to extend the
immune response to encompass patho-
genic antibodies and to produce overt
clinical PF. For example, in the endemic
form of PF, fogo selvagem, that is found
in rural areas of South America, it might
be possible that repeated modification of
Dsg1 by chronic or recurrent staphylo-
coccal infection in genetically suscepti-
ble individuals might trigger disease.
Thus, our data are consistent
with the hypothesis that a bacterial
toxin can modify a self-antigen to result
in an autoantibody response. The re-
levance of this finding to onset of
autoimmune diseases remains to be
proven.
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TO THE EDITOR
Atopic dermatitis (AD) is one of the
most common inflammatory skin dis-
orders characterized by pruritus, a
chronically relapsing course and typi-
cally distributed lesions with dry skin,
excoriations, and lichenification (Leung
et al., 2004). Topical treatment of acute
lesions with corticosteroids (CS) is a
mainstay in the therapy of the AD;
however, long-term application is limi-
ted by CS-related side effects (e.g., skin
atrophy) (Stoppolino et al., 1983). The
calcineurin inhibitors tacrolimus and
pimecrolimus are now available as
ointment/cream preparations and have
proven to be a novel option for the
topical treatment of AD (Ruzicka et al.,
1997; Luger et al., 2001).
AD skin lesions harbor a variety of
inflammatory cells, of which dendritic
cells (DCs) represent a major fraction.
Besides resident Langerhans cells and
inflammatory dendritic epidermal cells,
Abbreviations: AD, atopic dermatitis; BMV, beta-methasone-17-valerate; CS, corticosteroids;
DC, dendritic cell; MFI, mean fluorescence intensity; pDC, plasmacytoid DC
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